VEGF抑制剂在新生血管性青光眼治疗中的应用  

Application of anti-vaxular endothelial growth factor on the treatment of neovaxular glaucoma

作　　者：吴平[1] 李平华[1] 

机构地区：[1]重庆医科大学附属第一医院眼科,中国重庆市400016

出　　处：《国际眼科杂志》2015年第11期1899-1901,共3页International Eye Science

摘　　要：新生血管性青光眼(neovascular glaucoma,NVG)是一种常见的继发性青光眼,常继发于糖尿病性视网膜病变、视网膜中央静脉阻塞和视网膜缺血综合征。其发病机制复杂,传统的治疗方式虽然能短暂缓解高眼压、消退虹膜新生血管,但对NVG的长期控制效果并不明显。随着近年来对NVG发病机制的深入研究及VEGF抑制剂在眼科疾病中的使用,NVG的治疗迎来了新的曙光。本文就VEGF抑制剂在新生血管性青光眼治疗中的应用做一综述,以期为NVG的治疗提供新的思路。Neovascular glaucoma（NVG） is a common secondary glaucoma,often occurs secondary to diabetic retinopathy,central retinal vein occlusion and retinal ischemia syndrome.Its pathogenesis is complicated.Though conventional treatmentscan brieflyreduce elevated intraocular pressure,degenerate iris neovascularization,the long-term effect for controlling NVG is not obvious.The treatment of NVG ushers in a new dawn with the indepth study on the pathogenesis of NVG and the use of vascular endothelial growth factor（VEGF） inhibitors in ophthalmic diseases.In this paper,the applications of VEGF inhibitors on the treatment of neovascular glaucoma are reviewed to provide new thoughts for the treatment of NVG.

关 键 词：新生血管性青光眼 抗血管内皮生长因子药物 

分 类 号：R779.6[医药卫生—眼科]